Singapore is home to more than 30 corporate R&D centres for biomedical sciences and 100 locally incorporated biotechs as of 2020. Now, with the launch of JLABS Singapore, the biotech ecosystem has gotten a boost – innovative startups can tap on Johnson & Johnson’s wealth of insights and networks to pursue game-changing potential solutions for unmet healthcare needs.
JLABS and EDB have also partnered to help Singapore companies accelerate their early-stage discoveries into innovative medicines, medical technologies and healthcare solutions. Eight companies are the inaugural recipients of JLABS services and resources – Qritive, Alt Atlas, AVECRIS, ChemLex, Kinexcs, , Rebee Health, Respiree and Zymedi.
At a panel discussion at Singapore Week of Innovation and Technology (SWITCH) 2023, JLABS’ Melinda Richter cited Singapore’s rich talent pool, ease of doing business, stability, access to capital and growing Southeast Asian markets as factors that led to JLABS expanding its footprint here. EDB’s Heng-Tong CHOO pointed to Singapore’s ongoing efforts to grow its biotech ecosystem – through training talent, initiatives such as A*StartCentral and the Global Innovation Alliance, funding for research, innovation and enterprise, and support for corporate and venture funding.